scispace - formally typeset
Search or ask a question
Topic

Dalfopristin

About: Dalfopristin is a research topic. Over the lifetime, 696 publications have been published within this topic receiving 26621 citations. The topic is also known as: RP-54476 & Dalfopristina.


Papers
More filters
Journal ArticleDOI
01 Sep 1996-Drugs
TL;DR: Quinupristin-dalfopristin is bactericidal against streptococci and staphylococci but has weak or no bactericidal activity against enterococci.
Abstract: Quinupristin-dalfopristin (RP 59500) is an injectable streptogramin antibiotic. It possesses a wide spectrum of activity against Gram-positive bacteria including methicillin-resistant staphylococci, glycopeptide-resistant Enterococcus faecium and penicillin-resistant pneumococci. Quinupristin-dalfopristin has activity against some anaerobes and selected Gram-negative pathogens. Quinupristin-dalfopristin, by way synergism of between its 2 components, is unaffected by most forms of bacterial resistance. Rare forms of macrolide-lincosamide-streptogramin group B resistance may affect its activity ; however, at present the incidence of strains with this type of resistance remains low. Quinupristin-dalfopristin is bactericidal against streptococci and staphylococci but has weak or no bactericidal activity against enterococci. In a compassionate use programme, 67% of 95 evaluable patients with vancomycin-resistant Gram-positive infections or intolerant of vancomycin showed improvement with eradication of infection.

1 citations

Journal ArticleDOI
TL;DR: Nonsusceptibilty to quinupristin-dalfopristin (Q-D) was absent from 105 non-SCD- associated pneumococcal isolates but was present in 33/148 SCD-associated isolates, and one-third of the isolates harbored a known resistance mechanism.
Abstract: Sickle cell disease (SCD) is a risk factor for fatal pneumococcal infection. Nonsusceptibilty to quinupristin-dalfopristin (Q-D) was absent from 105 non-SCD-associated pneumococcal isolates but was present in 33/148 (22%) SCD-associated isolates. One-third of the isolates harbored a known resistance mechanism. Q-D is not optimal for use for the treatment of pneumococcal infection in SCD patients.
Posted ContentDOI
TL;DR: Very little resistance was found to linezolid, quinupristin/dalfopristin and tigecycline and these antibiotics may be beneficial for the proper treatment of infections caused by MLSB-resistant isolates.
Abstract: Objective: In this study, it was aimed to determine the in vitro susceptibilities of Methicillin-Resistant Staphylococcus aureus (MRSA) strains to fluoroquinolone, linezolid, tigecycline, and quinupristin/dalfopristin as well as the macrolide-lincosamide-streptogramin B (MLSB) resistance phenotype. Materials and Methods: A total of 94 MRSA strains isolated from various clinical samples in our hospital laboratory between January 2020 and September 2020 were included. The in-vitro susceptibilities of MRSA strains against fluoroquinolone, linezolid, tigecycline, and quinupristin/dalfopristin were determined by Kirby-Bauer disc diffusion assay according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST). The E test assay was used for evaluation of tigecycline susceptibility. The D-zone test was performed with erythromycin (15 μg) and clindamycin (2 μg) discs to determine the MLSB resistance. Besides, bacterial identification, antibiotic susceptibility tests including methicillin resistance and MLSB phenotype determination were performed by using VITEK 2 Gram-positive diagnostic kits (Bio-Merieux/France). Results: Results: Among 94 MRSA strains included, resistance rates to ciprofloxacin, moxifloxacin, tigecycline, and quinupristin/dalfopristin were found as 71% (67 isolates) 64% (60 isolates), 17% (16 isolates), and 2% (2 isolates), respectively. Resistance was not detected for linezolid. A total of 36 (49%) isolates showed cMLSB resistance phenotype, while 18(19%) had iMLSB resistance. The methicillin susceptibility (MS) phenotype – strains resistant to erythromycin and susceptible to clindamycin- was not detected. Conclusion: Very little resistance was found to linezolid, quinupristin/dalfopristin and tigecycline. Therefore, these antibiotics may be beneficial for the proper treatment of infections caused by MLSB-resistant isolates.
Journal ArticleDOI
TL;DR: In this paper , the authors assess the prevalence of Enterococcus spp. in wild birds in Poland, determination of antimicrobial susceptibility and WGS analysis of E. faecium and E. casseliflavus.
Abstract: Enterococci as opportunistic bacteria are important for human health. Due to the prevalence and ease of acquisition and transfer of their genes, they are an excellent indicator of environmental contamination and the spread of antimicrobial resistance. The aim of the study was to assess the prevalence of Enterococcus spp. in wild birds in Poland, determination of antimicrobial susceptibility and WGS analysis of Enterococcus (E.) faecium and E. faecalis. For this purpose, 138 samples from various species of free-living birds were tested, with 66.7% positive results. Fourteen species were detected, with E. faecalis being the most common, followed by E. casseliflavus and E. hirae. In antimicrobial susceptibility testing, 10.0% of E. faecalis and 50.0% of E. faecium showed resistance to one antimicrobial agent, in addition the MDR phenotype which was found in one E. faecium. The most common resistance phenotype included tetracycline and quinupristin/dalfopristin. The WGS analysis confirmed the significant advantage of the virulence gene diversity of E. faecalis strains over E. faecium. In addition, plasmid replicons were found in 42.0% of E. faecalis and 80.0% of E. faecium. The obtained results confirm free-living birds can be a reservoir of Enterococcus spp. with a considerable zoonotic potential.

Network Information
Related Topics (5)
Antibacterial agent
35.8K papers, 1.2M citations
82% related
Antibiotic resistance
29.1K papers, 884.5K citations
82% related
Staphylococcus aureus
27K papers, 779K citations
81% related
Pseudomonas aeruginosa
16.8K papers, 565.2K citations
81% related
Drug resistance
28.4K papers, 1.1M citations
80% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
20237
202217
20219
202010
201913
201811